NPC-REAAD™ is an in-vitro diagnostic intended for qualitative and semi-qualitative detection of IgA antibodies in human serum samples for nasopharyngeal carcinoma. It uses proprietary proteins developed by Restalyst to identify specific IGA antibody to EA seromarker segment. Detection of EA is associated with higher specificity in comparison to other EBV related markers, resulting in lesser false positive during screening. This is particularly important and is a feature that our customers especially value with NPC-REAAD™. Lesser false positive results reduce unnecessary worry to patients and the requirement for them to undergo unnecessary procedures or treatments.


About Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma (NPC) is a commonly diagnosed head and neck malignancy in Southeast Asia.It also occurs more frequently amongst males than females. Epstein-Barr virus is a knowncommon cause of infectious mononucleosis. After recovering, the EBV remains latent within the patient’s body and patients become life-long carriers. Studies have shown that Epstein Barr Virus (EBV) can result in cancerous nasopharynx cells, however this relationship is yet to be fully understood. EBV is one of the many contributing factors of NPC, which also includes genetics, dietary and other environmental factors.


About Internal Assessment Program

All customers are offered membership of our Internal Assessment Program. Participating laboratories can use the program to ensure continuous high quality NPC testing performance. This is the only NPC related program currently available in the region.